Cognoptix Announces Formation of a New Board of Directors News provided by Share this article Share this article MARLBOROUGH, Mass., Dec. 30, 2020 /PRNewswire/ -- Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. Susanne Wilke, Ph.D., Cognoptix' new President and CEO. In addition to Dr. Wilke, the five-member board incl...